RLAY
Relay Therapeutics Inc
18.00$
-4.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Relay Therapeutics Inc (RLAY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -54 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11 | -15 | -18 | -23 | -22 | -21 | -24 | -35 | 47 | -28 | -53 | -40 | -49 | -57 | -66 | -57 | -67 | -69 | -75 | -89 | -50 | -66 | -75 | -58 | -73 | -55 | -62 | -45 | -51 | -54 | -212 | |
| 0.7 | 0.7 | 0.6 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.2 | 1.2 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | -8.8 | 1.3 | 1.2 | -0.4 | 0.7 | -0.3 | 0.5 | 0.4 | 1.4 | |
| 0.8 | 1.1 | 1.2 | 1.3 | 1.5 | 4.0 | 12 | 15 | 9.7 | 16 | 12 | 10 | 13 | 15 | 14 | 14 | 22 | 23 | 22 | 19 | 27 | 27 | 22 | 18 | 19 | 15 | 16 | 13 | 11 | 9.2 | 48 | |
| 0.9 | 0.4 | 0.1 | – | 1.1 | 3.9 | 12 | 15 | 9.8 | 152 | 15 | 11 | 8.9 | 20 | 14 | 14 | 22 | 19 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.8 | 1.4 | 1.4 | -0.4 | 0.6 | 1.1 | -0.8 | -86 | 78 | 13 | -8.5 | 15 | 2.4 | 2.8 | -0.3 | 6.4 | 7.4 | 9.5 | -29 | -21 | 8.0 | 13 | -21 | 1.4 | -15 | -1.9 | -3.5 | -2.8 | 12 | 21 | 26 | |
| 3.1 | 1.9 | 2.4 | 0.6 | 1.0 | 0.4 | 0.4 | 0.1 | 0.5 | 0.4 | 1.7 | 0.9 | 2.8 | 1.9 | 2.1 | 2.3 | 1.9 | 1.5 | 0.6 | 0.1 | 1.8 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -3.1 | -359 | 7.1 | 36 | 50 | 88 | 20 | -76 | -234 | 26 | 21 | -293 | -112 | 43 | 27 | -147 | 75 | 51 | 71 | 60 | 11 | 46 | -126 | 29 | 42 | 75 | 40 | 35 | 33 | -353 | -245 | |
| 5.0 | – | – | – | 0.4 | – | – | -2.5 | 2.1 | 1.1 | 0.9 | 1.8 | 0.9 | 2.0 | 1.1 | -2.3 | – | – | – | – | – | – | 1.1 | – | – | 0.7 | – | 0.4 | – | – | – | |
| 5.0 | 0.7 | 0.1 | -0.2 | 0.4 | -0.1 | 426 | 0.1 | 2.1 | 1.1 | 0.9 | 384 | 0.9 | 2.0 | 286 | 1.2 | 1.3 | 2.1 | 9.5 | 22 | 49 | 1.5 | 219 | 0.8 | 0.0 | 0.7 | 0.0 | 0.9 | 139 | 324 | 463 | |
| -8.9 | -373 | -10 | 13 | 28 | 67 | 422 | -112 | -185 | -1.0 | -32 | 52 | -161 | -12 | 247 | -203 | 9.5 | -15 | 5.4 | -7.6 | 9.1 | -19 | 18 | -28 | -31 | 21 | -22 | -8.5 | 121 | -83 | 6.3 | |
| -14 | -17 | -20 | -23 | -23 | -21 | -24 | -35 | 46 | -29 | -55 | -41 | -52 | -59 | -68 | -59 | -69 | -70 | -76 | -89 | -52 | -66 | -75 | -58 | -74 | -55 | -62 | -45 | -51 | -54 | -212 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.